title: What is the most effective treatment for severe gastro-oesophageal reflux disease?
authors.affiliation: Upper Gastrointestinal Surgery, Department of Molecular Medicine and Surgery, Karolinska Institutet, Norra Stationsgatan 67, 171 76, Stockholm, Sweden.
authors.forename: John
authors.initials: J
authors.lastname: Maret-Ouda
authors.affiliation: Upper Gastrointestinal Surgery, Department of Molecular Medicine and Surgery, Karolinska Institutet, Norra Stationsgatan 67, 171 76, Stockholm, Sweden.
authors.forename: Nele
authors.initials: N
authors.lastname: Brusselaers
authors.affiliation: Upper Gastrointestinal Surgery, Department of Molecular Medicine and Surgery, Karolinska Institutet, Norra Stationsgatan 67, 171 76, Stockholm, Sweden Section of Gastrointestinal Cancer, Division of Cancer Studies, King's College London, Guy's and St Thomas' NHS Foundation Trust, London SE1 7EH, UK jesper.lagergren@ki.se.
authors.forename: Jesper
authors.initials: J
authors.lastname: Lagergren
mesh_terms: D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D001471:Barrett Esophagus / Q000209:etiology / Q000517:prevention & control*; D003362:Cost-Benefit Analysis; D004942:Esophagitis, Peptic / Q000209:etiology / Q000517:prevention & control*; D018662:Fundoplication / Q000379:methods*; D005764:Gastroesophageal Reflux / Q000150:complications / Q000628:therapy*; D006801:Humans; D054328:Proton Pump Inhibitors / Q000627:therapeutic use*; D011788:Quality of Life; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
chemical_list: D000897:Anti-Ulcer Agents; D054328:Proton Pump Inhibitors